NMTC vs. SGHT, PROF, TLSI, INGN, BSGM, KRMD, ELMD, PDEX, LNSR, and RCEL
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Sight Sciences (SGHT), Profound Medical (PROF), TriSalus Life Sciences (TLSI), Inogen (INGN), Biosig Technologies (BSGM), KORU Medical Systems (KRMD), Electromed (ELMD), Pro-Dex (PDEX), LENSAR (LNSR), and Avita Medical (RCEL). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs. Its Competitors
Sight Sciences (NASDAQ:SGHT) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Sight Sciences has a net margin of -63.24% compared to NeuroOne Medical Technologies' net margin of -75.41%. Sight Sciences' return on equity of -54.62% beat NeuroOne Medical Technologies' return on equity.
In the previous week, Sight Sciences had 3 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 5 mentions for Sight Sciences and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.94 beat Sight Sciences' score of 0.46 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Sight Sciences. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Sight Sciences presently has a consensus target price of $3.93, suggesting a potential upside of 12.38%. NeuroOne Medical Technologies has a consensus target price of $1.45, suggesting a potential upside of 61.47%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Sight Sciences.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Sight Sciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Summary
Sight Sciences beats NeuroOne Medical Technologies on 10 of the 16 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 7/25/2025 by MarketBeat.com Staff
